# Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients

> **NCT01974258** · PHASE1 · WITHDRAWN · sponsor: **Hoffmann-La Roche**

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Cobimetinib
- **DRUG:** Cobimetinib
- **DRUG:** Onartuzumab
- **DRUG:** Vemurafenib

## Key facts

- **NCT ID:** NCT01974258
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-02
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01974258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01974258, "Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01974258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*